Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patientsGianmaria Baldin, Simona Di Giambenedetto, Arturo Ciccullo et al.|International Journal of Antimicrobial Agents|2019Cited by 55
A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected PatientsArturo Ciccullo, Simona Di Giambenedetto, Amedeo Capetti et al.|Antiviral Therapy|2018Cited by 37
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive FindingArturo Ciccullo, Gianmaria Baldin, Vanni Borghi et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 34
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort studyBarbara Rossetti, Giordano Madeddu, Gianmaria Baldin et al.|Antiviral Research|2019Cited by 32
Efficacy and durability of two‐ <i>vs</i>. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohortMassimiliano Fabbiani, Barbara Rossetti, Arturo Ciccullo et al.|HIV Medicine|2021Cited by 31